Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Tombetti, Enrico ^a,b   Di Chio, Chiara ^a,b   Sartorelli, Silvia ^a,b   Papa, Maurizio ^a   Salerno, Annalaura ^a,b   Bottazzi, Barbara ^c   Bozzolo, Paola ^a   Greco, Marta ^c   Rovere Querini, Patrizia ^a,b   Baldissera, Elena ^a,b   Del Maschio, Alessandro ^a,b   Mantovani, Alberto ^c,d   De Cobelli, Francesco ^a,b   Sabbadini, Grazia ^a,b   Manfredi, Angelo A ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PATTERN RECOGNITION RECEPTOR; PENTRAXIN 3; SERUM AMYLOID P; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; AGED; ANGIOGRAPHY DEVICE; AORTA ARCH SYNDROME; ARTERY CALCIFICATION; ARTERY LESION; ARTERY WALL; ARTICLE; BIOSYNTHESIS; BLOOD; BLOOD VESSEL WALL; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN BLOOD LEVEL; REAL TIME ULTRASOUND SCANNER; REMISSION; SEDIMENTATION RATE; SEX RATIO; TAKAYASU ARTERITIS; VASCULAR ENDOTHELIUM; VASCULITIS; WHOLE BODY SCANNER; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; BIOSYNTHESIS; BLOOD; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIAGNOSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SERUM AMYLOID P-COMPONENT; TAKAYASU ARTERITIS; YOUNG ADULT;

EID: 84924340870     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0479-z     Document Type: Article

References (42)

1. Mason JC: Takayasu arteritis-advances in diagnosis and management. Nat Rev Rheumatol 2010, 6:406-415.
2. Maksimowicz-McKinnon K, Hoffman GS: Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 2007, 33:777-786. vi.
3. Freitas DS, Camargo CZ, Mariz HA, Arraes AE, de Souza AW: Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012, 32:703-709.
4. Arnaud L, Haroche J, Limal N, Toledano D, Gambotti L, Costedoat Chalumeau N, Le Thi Huong Boutin D, Cacoub P, Cluzel P, Koskas F, Kieffer E, Piette JC, Amoura Z: Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore) 2010, 89:1-17.
5. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS: Takayasu arteritis. Ann Intern Med 1994, 120:919-929.
6. Hoffman GS, Ahmed AE: Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 1998, 66:S191-S194. discussion S195.
7. Maksimowicz-McKinnon K, Clark TM, Hoffman GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007, 56:1000-1009.
8. Tombetti EMA, Sabbadini MG, Baldissera E: Management options for Takayasu arteritis. Expert Opin Orphan Drugs 2013, 1:685-693.
9. Ishikawa K, Maetani S: Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994, 90:1855-1860.
10. Youngstein T, Mason JC: Interleukin 6 targeting in refractory Takayasu arteritis: serial noninvasive imaging is mandatory to monitor efficacy. J Rheumatol 2013, 40:1941-1944.
11. Tombetti E, Di Chio MC, Sartorelli S, Bozzolo E, Sabbadini MG, Manfredi AA, Baldissera E: Anti-cytokine treatment for Takayasu arteritis: state of the art. Intractable Rare Dis Res 2014, 3:29-33.
12. Inforzato A, Jaillon S, Moalli F, Barbati E, Bonavita E, Bottazzi B, Mantovani A, Garlanda C: The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens 2011, 77:271-282.
13. Mantovani A, Valentino S, Gentile S, Inforzato A, Bottazzi B, Garlanda C: The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann NY Acad Sci 2013, 1285:1-14.
14. Ma YJ, Doni A, Romani L, Jurgensen HJ, Behrendt N, Mantovani A, Garred P: Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. J Immunol 2013, 191:1324-1333.
15. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, D'Auria F, Praderio L, Ciboddo G, Sabbadini MG, Manfredi AA, MAntovani A, Querini PR: PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001, 44:2841-2850.
16. van Rossum AP, Pas HH, Fazzini F, Huitema MG, Limburg PC, Jonkman MF, Kallenberg CG: Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006, 54:986-991.
17. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-Gonzalez S, Corbera-Bellalta M, Comite GD, Papa I, Dell'antonio G, Ammirati E, Cuccovillo I, Vecchio V, Mantovani A, Rovere-Querini P, Sabbadini MG, Cid MC, Manfredi AA: Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 2012, 64:854-865.
18. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, Manfredi AA, Baldissera E, Sabbadini MG: Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011, 155:425-433.
19. Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, Isobe M: Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 2011, 57:1712-1713.
20. Ishihara T, Haraguchi G, Tezuka D, Kamiishi T, Inagaki H, Isobe M: Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J 2013, 77:477-483.
21. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990, 33:1129-1134.
22. Vouret-Craviari V, Cenzuales S, Poli G, Mantovani A: Expression of monocyte chemotactic protein-3 in human monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Cytokine 1997, 9:992-998.
23. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R: PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
24. Papa M, De Cobelli F, Baldissera E, Dagna L, Schiani E, Sabbadini M, Del Maschio A: Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity. AJR Am J Roentgenol 2012, 198:W279-W284.
25. Hata A, Noda M, Moriwaki R, Numano F: Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 1996, 54:S155-S163.
26. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A: Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008, 20:538-544.
27. Bottazzi B, Doni A, Garlanda C, Mantovani A: An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010, 28:157-183.
28. Bonacina F, Baragetti A, Catapano AL, Norata GD: Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013, 2013:725102.
29. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL: Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120:699-708.
30. Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, Mantovani A, Giacca M, Presta M: Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005, 25:1837-1842.
31. Haybar H, Assareh A, Ghotbi Y, Torabizadeh M, Bozorgmanesh M: Incremental diagnostic value of circulating pentraxin in patients with intermediate risk of coronary artery disease. Heart 2013, 99:640-648.
32. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA: Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J 2012, 163:274-279.
33. Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS, Psaty BM: Associations of Pentraxin 3 with cardiovascular disease: the multi-ethnic study of atherosclerosis. J Thromb Haemost 2014, 12:999-1005.
34. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E: Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 2013, 40:2047-2051.
35. Bonilla-Abadia F, Canas CA, Echeverri AF: Outcomes of patients with takayasu arteritis treated with infliximab. J Rheumatol 2013, 40:1930-1931.
36. Weyand CM, Goronzy JJ: Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013, 9:731-740.
37. Bauer E, Chanthaphavong RS, Sodhi CP, Hackam DJ, Billiar TR, Bauer PM: Genetic deletion of TLR4 on platelets attenuates experimental pulmonary hypertension. Circ Res 2014, 114:1596-1600.
38. Lowe HC, Oesterle SN, Khachigian LM: Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002, 39:183-193.
39. Joviliano EE, Piccinato CE, Dellalibera-Joviliano R, Moriya T, Evora PR: Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts. Ann Vasc Surg 2011, 25:846-855.
40. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A: Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994, 84:3483-3493.
41. Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS: Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002, 46:1634-1642.
42. Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G, Kas A, Costedoat-Chalumeau N, Cacoub P, Toledano D, Cluzel P, Piette JC, Amoura Z: Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 2009, 60:1193-1200.